Business in Brief
The latest industry news – in 60 words or less
Phoebe Harkin | | Quick Read
- Samsung Bioepis and Biogen, Inc., announced that the European Medicines Agency has accepted for review its Marketing Authorisation Application for SB11. If approved, the drug – a proposed biosimilar for ranibizumab (Lucentis) – will join a growing number of biosimilars developed by Samsung Bioepis and commercialized by Biogen.
- The oldest optical organization in the world, The Worshipful Company of Spectacle Makers, has launched a new nonprofit, The Spectacle Makers’ Charity. This initiative combines two previous grant-giving trusts, one promoting support for optical education and the other for organizations helping vision-impaired people. They have previously given over £70,000 a year to students, trainee ophthalmologists, and charities worldwide.
- At Euretina, Oculis presented positive results from its Phase II trial of OCS-01 in patients with DME. The study met its pre-specified efficacy endpoints, showing that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity. No adverse side effects were observed.
- The IAPB has announced a record-breaking number of Eye Health Heroes to mark World Sight Day 2020. The 52 heroes hail from 27 countries and have been praised by IAPB Global Ambassador, HRH The Countess of Wessex, for their work on the frontline, “adapting to deliver vital services and support the response to this global pandemic.”
- Jena-based medical technology manufacturer Imedos Systems GmbH has entered a new partnership with Aifei Electronic Technology Co., Ltd. The company now distributes RCrodent systems, which enabling contactless retinal imaging and vessel analysis in particularly small eyes (such as rodents and small animals), paving the way for lab-based research projects.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Ophthalmologist site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine